Search
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.
Raltitrexed
go.drugbank.com/drugs/DB00293ApprovedInvestigationalRaltitrexed (brand name Tomudex®) is a chemotherapy drug manufactured AstraZeneca Company, is an antimetabolite used in chemotherapy. It is an inhibitor of thymidylate synthase.
GLPG-1205
go.drugbank.com/drugs/DB15346InvestigationalGLPG-1205 is under investigation in clinical trial NCT03725852 (A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)).
XL019
go.drugbank.com/drugs/DB05243InvestigationalAn IND for XL019 was filed by Exelixis in May 2007.
Kebuzone
go.drugbank.com/drugs/DB08940InvestigationalKebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.
Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDSZeranol
go.drugbank.com/drugs/DB11478ExperimentalVet approvedZeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops.
Categories: Estrogens, Non-SteroidalZD4407
go.drugbank.com/drugs/DB06539ExperimentalIt entered Phase 1 clinical trials for chronic obstructive pulmonary disease (COPD) in the United Kingdom but was discontinued during this phase in March 2003 … The drug ZD4407, an antiasthmatic developed by AstraZeneca, functions as a 5-lipoxygenase inhibitor.
Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10781ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen
Mixtures: Physicians EZ Use Flu Kit, Medical Provider Single Use EZ Flu Shot KitGaradacimab
go.drugbank.com/drugs/DB15629Approved[A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283] It was developed by CSL Behring for use as a prophylactic agent in patients with hereditary angioedema (HAE), a rare autosomal dominant disorder that results in acute episodes of angioedema.
Vinblastine
go.drugbank.com/drugs/DB00570ApprovedInvestigationalAntitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)